Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib vs Ibrutinib in Previously Treated High Risk CLL
NCT02477696Phase 3Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Jul 2015
- Primary completion
- Sep 2020
- Countries
- 15
01
Overview
A Phase 3 trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), sponsored by Acerta Pharma. Started Jul 2015; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02477696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477696.